ALTSTATION.IO

Intuitive Surgical, Inc. (ISRG) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$488.83

Change

+2.63%

Market Cap

$173.60B

Avg Volume

1.9M

Company Overview

Intuitive Surgical, Inc. designs and sells advanced robotic surgical systems, primarily the da Vinci Surgical System, which allows for minimally invasive surgeries. Their products cater to hospitals and healthcare providers both domestically and internationally. They have expanded their offerings with the Ion endoluminal system, which enables minimally invasive lung biopsies, enhancing their portfolio beyond traditional surgery. The company also provides a comprehensive suite of instruments and services that support these systems, including maintenance and technical support.

Intuitive Surgical is the clear market leader in robotic surgical systems, holding a significant share of the global market. Their cutting-edge technology and comprehensive support services give them an edge over competitors like Medtronic and Stryker. However, they face challenges from emerging technologies in the surgical space, as well as price pressures and competition from alternative treatments. The growing emphasis on cost-effective healthcare solutions may also influence their market position in the coming years.

Currently, Intuitive Surgical is in a growth phase, showing strong demand for its systems despite economic headwinds. In their most recent quarterly report, they reported revenue growth of approximately 12% year-over-year, driven largely by an increase in da Vinci system placements and procedures. They continue to invest in R&D to enhance their technology and expand their product offerings, positioning themselves for sustained long-term growth in the healthcare sector.

Key Financials

Market Cap

$173.60B

Revenue

$10.06B

EBITDA

$3.56B

Gross Margin

66.0%

Profit Margin

28.4%

Revenue Growth

18.8%

Total Cash

$5.93B

Total Debt

$170.90M

Free Cash Flow

$2.27B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

62.19

Forward P/E

42.74

Beta

1.66

52-Week High

$609.08

52-Week Low

$425.00

EPS

$7.86

50-Day Avg

$552.16

200-Day Avg

$516.38

Price/Book

9.74

Technical Analysis

Over the past 52 weeks, Intuitive Surgical, Inc. (ISRG) has exhibited a clearly bearish trend, with a significant decline of 18.1% from its previous highs near $600 in March to the current price of $488.83. The key resistance level remains around $600, while strong support has been established near the $450 mark. The chart indicates a descending triangle pattern, suggesting continued selling pressure, especially given the multiple tests of support and failure to reclaim higher levels. Recent momentum has been negative, particularly in late January and early February, where the stock’s price retraced sharply after failing to break above the 50-day moving average around $530. Currently, at $488.83, the stock is nearing the lower end of its 52-week range, implying a challenging environment for bullish sentiment unless a reversal can materialize above key resistance.

Recent News and Developments

Here’s a summary of the latest news and developments for Intuitive Surgical, Inc

(ISRG) stock from February 1 to February 7, 2026:

1. Regulatory Approval Expands Da Vinci 5 Cardiac Procedures

Intuitive Surgical’s flagship da Vinci 5 robotic system recently received FDA clearance for use in certain cardiac procedures, including mitral valve repair and internal mammary artery mobilization for cardiac revascularization. This regulatory approval is estimated to expand the total addressable market by approximately 160,000 procedures annually, signaling new growth opportunities for the company.

2. Analyst Upgrades Point to Underestimated Long-Run Growth

During the past week, TD Cowen upgraded Intuitive Surgical, stating that the company’s long-run growth is likely underestimated and supporting a higher multi-year earnings outlook. Freedom Capital Markets also upgraded ISRG to a Buy rating on January 27, 2026, setting a price target of $610.00, citing optimism around the da Vinci 5 rollout.

Market Sentiment and Analyst Recommendations

Bull Case

The FDA approval for da Vinci 5 cardiac procedures is a material catalyst that expands the addressable market by 160,000 procedures annually — a genuine new revenue stream. Q4 2025 results were solid: $2.87B revenue (+19% YoY) and $2.53 adjusted EPS (+14% YoY) show the core business is still firing. Two major analyst upgrades in the past week from TD Cowen and Freedom Capital Markets signal institutional conviction that long-term growth is underestimated. The company sits on $5.93B in cash with minimal debt ($170.9M), giving them firepower for R&D and M&A without financial strain. At a 62 P/E multiple, ISRG is expensive, but 31 analysts recommend buy with a median target of $611.82 — that’s 25% upside from current levels. The installed base of da Vinci systems creates recurring revenue through procedure kits and maintenance, a durable moat that compounds over time.

Bear Case

The stock is down 18.1% from its $609 high in March and trading near the bottom of its 52-week range at $488.83, suggesting real weakness despite positive news. 2026 guidance projects procedure growth of only 13-15%, a meaningful deceleration from 2025’s pace — that’s a red flag for a company trading at 62x earnings. The descending triangle pattern on the chart indicates continued selling pressure and failed breakout attempts above $530, showing technicals are broken. At $173.6B market cap, ISRG is pricing in perfection; even modest execution misses could trigger further downside given the high multiple. Procedure growth guidance implies the cardiac expansion and da Vinci 5 rollout may already be baked into expectations, leaving limited surprise upside. Macro headwinds in healthcare spending and hospital capex budgets could constrain procedure volume growth further, especially if elective procedures face pressure.

What to Watch

Monitor Q1 2026 procedure growth numbers when reported in April — the 13-15% guidance is the floor, so anything below that breaks the bull thesis. Track da Vinci 5 cardiac adoption rates specifically; if hospitals are slow to convert or procedure volumes disappoint, the 160,000 procedure TAM expansion is overstated. Watch for analyst estimate revisions over the next 60 days; if more upgrades follow TD Cowen and Freedom Capital, that’s accumulation. The $530-550 zone is critical resistance on the chart — a sustained break above $550 would invalidate the descending triangle and suggest institutional buying has returned. Keep tabs on hospital capex spending trends and elective procedure volumes in healthcare reports; a recession or sharp slowdown in discretionary hospital spending would pressure growth. If the stock can’t hold the $450 support level, expect test of $425 and potential capitulation selling.

Analyst Consensus

BUY

Based on 31 analyst opinions

Low Target

$378.00

Mean Target

$611.82

High Target

$750.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

17,021

Earnings & Dividends

Next Earnings

Apr 21, 2026

EPS (Trailing)

$7.86

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is ISRG a good stock to buy?

Yes, Intuitive Surgical is rated as a BUY by analysts, with a target price of $611.82. Given its strong market cap of $173.60 billion, the company has solid growth potential in the healthcare sector.

What is ISRG’s price target?

Analysts have set a target price of $611.82 for ISRG. This represents an upside of about 25% from the current price of $488.83.

Does ISRG pay a dividend?

No, Intuitive Surgical does not currently pay a dividend. This is common in growth-oriented companies that reinvest profits into expanding operations.

What’s ISRG’s P/E ratio?

ISRG has a P/E ratio of 62.19 and a forward P/E of 42.74. These figures indicate that investors are willing to pay a premium for future earnings, reflecting strong growth expectations.

What has been the stock’s price range over the last year?

Over the past year, ISRG’s stock has traded between $425.00 and $609.08. This volatility underscores the market’s mixed sentiment but also highlights the potential for price appreciation.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.